Prospective post-marketing surveillance of sodium-glucose cotransporter 2 inhibitor, canagliflozin, for the treatment of CKD with type 2 diabetes

Prospective post-marketing surveillance of sodium-glucose cotransporter 2 inhibitor, canagliflozin, for the treatment of CKD with type 2 diabetes - PEARL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050085

Enrollment

1000

Registered

2023-02-02

Start date

2023-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease with type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with CKD complicated with type 2 diabetes who have never taken CANAGLU 100 mg tablets

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
<Safety> - Occurrence of adverse drug reactions during the observation period - Effects of patient characteristics on the risk of adverse drug reactions <Efficacy> - Time-course change in renal function (eGFR) - Effects of patient characteristics on efficacy	—

Countries

Japan

Contacts

Public ContactMihoko Hata

Tanabe Pharma Corporation Pharmacovigilance Department

tp-pms-shinchoku.JP@ml.tanabe-pharma.com06-6205-5223

Outcome results